| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
304 |
| Employees |
12 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-14 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Mymetics Corporation is a biotechnology company specializing in the development of novel vaccine and drug delivery technologies. The company focuses on creating innovative solutions to improve the efficacy and safety of vaccines and drugs.
Mymetics' core technology, called virosome-based vaccine adjuvants, involves the reengineering of viruses to enable them to deliver antigens effectively to the immune system for a robust immune response. This approach allows for the development of vaccines against various infectious diseases, including respiratory syncytial virus (RSV), malaria, and HIV.
Additionally, the company is involved in research and development related to mucosal drug delivery, aiming to enhance the effectiveness and convenience of drug administration through the mucosal surfaces of the body. They leverage their expertise in virosome technology for this purpose as well.
Mymetics collaborates with various partners, including pharmaceutical companies, governmental organizations, and research institutes, to advance their technologies and bring their products to market. They also actively seek partnerships and licensing opportunities to further expand their reach and impact in the field of vaccine and drug delivery.
Overall, Mymetics Corporation is dedicated to pioneering innovative approaches in vaccine and drug delivery to address critical global health challenges and improve patient outcomes.
Company Address: c/o Mymetics SA Epalinges 1066
Company Phone Number: 41 21 566 57 72 Stock Exchange / Ticker: MYMX
|
0.000%
12.96% 